Loading...
XJPX
3151
Market cap445mUSD
Oct 09, Last price  
1,476.00JPY
1D
0.82%
1Q
-5.38%
Jan 2017
49.09%
IPO
180.61%
Name

Vital Ksk Holdings Inc

Chart & performance

D1W1MN
XJPX:3151 chart
P/E
9.64
P/S
0.12
EPS
153.14
Div yield, %
3.96%
Shrs. gr., 5y
-2.58%
Rev. gr., 5y
2.60%
Revenues
610.50b
+1.69%
534,698,000,000532,053,000,000541,636,000,000547,590,000,000564,645,000,000548,007,000,000620,978,000,000581,117,000,000565,587,000,000559,718,000,000562,529,000,000537,058,000,000577,249,000,000579,772,000,000587,481,000,000600,370,000,000610,497,000,000
Net income
7.36b
+0.73%
2,786,000,000-1,067,000,0003,154,000,0003,908,000,0004,235,000,0004,527,000,0006,556,000,0004,778,000,0004,467,000,0005,084,000,0004,642,000,0001,171,000,0004,770,000,0004,831,000,0005,843,000,0007,309,000,0007,362,000,000
CFO
4.83b
P
3,005,000,0005,226,000,00012,863,000,00010,123,000,000-10,409,000,0009,515,000,000-2,350,000,0001,116,000,00016,783,000,00018,229,000,000-8,323,000,000-1,389,000,0007,487,000,000-3,001,000,00023,570,000,000-8,024,000,0004,833,000,000
Dividend
Mar 30, 202735 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Vital KSK Holdings, Inc. is a Japanese entity primarily involved in the wholesale distribution of pharmaceutical products. Its diverse wholesale operations also cover veterinary medications, agricultural chemicals and supplies, and various types of medical and nursing care equipment. Beyond its core distribution activities, the company manages a range of services including operating pharmacies, providing nursing care, transportation, insurance agency services, real estate management, and parking facilities. It also runs a mail-order business focused on health-related products and offers pharmacy dispensing services. Furthermore, Vital KSK Holdings provides medical management consulting and manufactures over-the-counter (OTC) drugs. The company was established in 2009 and maintains its headquarters in Tokyo, Japan.

Key people

Akira Teramura
Executive Officer, Director of Sales and Purchasing · since 2023
Hiroshi Hiratani
Executive Officer, Senior Director of GDP · since 2024
Shigemi Naito
Executive Officer, Director of General Affairs & Human Resources · since 2023
Kenta Sato
Executive Officer, Director of Corporate Communications · since 2023
Hideo Takeda
Executive Officer, Director of Legal Compliance · since 2023
Hiroshi Yokoyama
Executive Officer, Director in charge of Business Planning Unit, Director in charge of Corporate Communications · since 2024
Takeshi Ichijo
Vice President, President of Subsidiary, Representative Director · since 2021
Toshiyuki Iguchi
Director · since 2021
Isao Kita
Director · since 2025
Taisuke Murai
President, Chief Executive Officer, Chief Information Officer, Representative Director · since 2017
Takashi Nishimaki
Director · since 2024
Soichiro Okamoto
Vice President, President of Subsidiary, Representative Director · since 2020
Mitsunao Suzuki
Director · since 2023
Koichiro Suzuki
Director · since 2023
Kiharu Takahashi
Director · since 2025
Jun Katsura
Independent Director · since 2023
Tsuyoshi Nishitani
Independent Director · since 2023
Kieko Onoki
Independent Director · since 2023
Seiya Takahashi
Independent Director · since 2023
Masami Tsugita
Independent Director · since 2023
URL
https://www.vitalksk.co.jp/
IPO date
Apr 01, 2009
Employees
3,719
Domiciled in
JP
Incorporated in
JP
Headquarters & legal address
弦巻１－１－１２
東京都 世田谷区 154-0016
JP
Address
1-1-12,Tsurumaki
Setagaya-ku Tokyo 154-0016
JP
Other language
VITAL KSK HOLDINGS,INC.

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT